CTLA4 and hepatocellular carcinoma: Meanwhile, expression of immune checkpoint genes such as CTLA4, HAVCR2, and TIGIT are reduced in T cells from recurrent tumors compared to the primary tumors, suggesting that checkpoint blockade approaches may be effective in primary HCC but not in recurrent tumors.